skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Single Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer
Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer

Torres-Adorno, Angie M ; Lee, Jangsoon ; Kogawa, Takahiro ; Ordentlich, Peter ; Tripathy, Debu ; Lim, Bora ; Ueno, Naoto T

Clinical cancer research, 2017-08, Vol.23 (16), p.4780-4792 [Periódico revisado por pares]

United States: American Association for Cancer Research Inc

Texto completo disponível

Citações Citado por
2
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Masuda, Norikazu ; Lee, Soo-Jung ; Ohtani, Shoichiro ; Im, Young-Hyuck ; Lee, Eun-Sook ; Yokota, Isao ; Kuroi, Katsumasa ; Im, Seock-Ah ; Park, Byeong-Woo ; Kim, Sung-Bae ; Yanagita, Yasuhiro ; Ohno, Shinji ; Takao, Shintaro ; Aogi, Kenjiro ; Iwata, Hiroji ; Jeong, Joon ; Kim, Aeree ; Park, Kyong-Hwa ; Sasano, Hironobu ; Ohashi, Yasuo ; Toi, Masakazu

The New England journal of medicine, 2017-06, Vol.376 (22), p.2147-2159 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
3
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Material Type:
Artigo 		Adicionar ao Meu Espaço

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Pan, Hongchao ; Gray, Richard ; Braybrooke, Jeremy ; Davies, Christina ; Taylor, Carolyn ; McGale, Paul ; Peto, Richard ; Pritchard, Kathleen I ; Bergh, Jonas ; Dowsett, Mitch ; Hayes, Daniel F

The New England journal of medicine, 2017-11, Vol.377 (19), p.1836-1846 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
4
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Saura, Cristina ; Oliveira, Mafalda ; Feng, Yin-Hsun ; Dai, Ming-Shen ; Chen, Shang-Wen ; Hurvitz, Sara A ; Kim, Sung-Bae ; Moy, Beverly ; Delaloge, Suzette ; Gradishar, William ; Masuda, Norikazu ; Palacova, Marketa ; Trudeau, Maureen E ; Mattson, Johanna ; Yap, Yoon Sim ; Hou, Ming-Feng ; De Laurentiis, Michelino ; Yeh, Yu-Min ; Chang, Hong-Tai ; Yau, Thomas ; Wildiers, Hans ; Haley, Barbara ; Fagnani, Daniele ; Lu, Yen-Shen ; Crown, John ; Lin, Johnson ; Takahashi, Masato ; Takano, Toshimi ; Yamaguchi, Miki ; Fujii, Takaaki ; Yao, Bin ; Bebchuk, Judith ; Keyvanjah, Kiana ; Bryce, Richard ; Brufsky, Adam

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3138-3149 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
5
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Shepherd, Jonathan H ; Ballman, Karla ; Polley, Mei-Yin C ; Campbell, Jordan D ; Fan, Cheng ; Selitsky, Sara ; Fernandez-Martinez, Aranzazu ; Parker, Joel S ; Hoadley, Katherine A ; Hu, Zhiyuan ; Li, Yan ; Soloway, Matthew G ; Spears, Patricia A ; Singh, Baljit ; Tolaney, Sara M ; Somlo, George ; Port, Elisa R ; Ma, Cynthia ; Kuzma, Charles ; Mamounas, Eleftherios ; Golshan, Mehra ; Bellon, Jennifer R ; Collyar, Deborah ; Hahn, Olwen M ; Hudis, Clifford A ; Winer, Eric P ; Partridge, Ann ; Hyslop, Terry ; Carey, Lisa A ; Perou, Charles M ; Sikov, William M

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1323-1334 [Periódico revisado por pares]

United States: Wolters Kluwer Health

Texto completo disponível

Citações Citado por
6
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

Litton, Jennifer K ; Scoggins, Marion E ; Hess, Kenneth R ; Adrada, Beatriz E ; Murthy, Rashmi K ; Damodaran, Senthil ; DeSnyder, Sarah M ; Brewster, Abenaa M ; Barcenas, Carlos H ; Valero, Vicente ; Whitman, Gary J ; Schwartz-Gomez, Jill ; Mittendorf, Elizabeth A ; Thompson, Alastair M ; Helgason, Thorunn ; Ibrahim, Nuhad ; Piwnica-Worms, Helen ; Moulder, Stacy L ; Arun, Banu K

Journal of clinical oncology, 2020-02, Vol.38 (5), p.388-394 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
7
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Davies, C ; Godwin, J ; Gray, R ; Clarke, M ; Cutter, D ; Darby, S ; McGale, P ; Pan, H C ; Taylor, C ; Wang, Y C ; Dowsett, M ; Ingle, J ; Peto, R

The Lancet (British edition), 2011-08, Vol.378 (9793), p.771-784 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

Coleman, R ; Powles, T ; Paterson, A ; Gnant, M ; Anderson, S ; Diel, I ; Gralow, J ; von Minckwitz, G ; Moebus, V ; Bergh, J ; Pritchard, KI ; Bliss, J ; Cameron, D ; Evans, V ; Pan, H ; Peto, R ; Bradley, R ; Gray, R ; Bartsch, R ; Dubsky, P ; Fesl, C ; Fohler, H ; Greil, R ; Jakesz, R ; Lang, A ; Luschin-Ebengreuth, G ; Marth, C ; Mlineritsch, B ; Samonigg, H ; Singer, CF ; Steger, GG ; Stoger, H ; Olivotto, I ; Ragaz, J ; Christiansen, P ; Ejlertsen, B ; Ewertz, M ; Jensen, MB ; Moller, S ; Mouridsen, HT ; Eiermann, W ; Hilfrich, J ; Jonat, W ; Kaufmann, M ; Kreienberg, R ; Schumacher, M ; Blohmer, JU ; Costa, SD ; Eidtmann, H ; Gerber, B ; Jackisch, C ; Loibl, S ; Dafni, U ; Markopoulos, C ; Blomqvist, C ; Saarto, T ; Ahn, JH ; Jung, KH ; Perrone, F ; Bass, G ; Brown, A ; Bryant, J ; Costantino, J ; Dignam, J ; Fisher, B ; Geyer, C ; Mamounas, EP ; Paik, S ; Redmond, C ; Swain, S ; Wickerham, L ; Wolmark, N ; Perez, E ; Ingle, JN ; Suman, VJ ; Hadji, P ; A'Hern, R ; Dowsett, M ; Makris, A ; Parton, M ; Pennert, K ; Powles, TJ ; Smith, IE ; Yarnold, JR ; Clack, G ; Van Poznak, C ; Safra, T ; Bell, R ; Coleman, RE ; Dodwell, D ; Hinsley, S ; Marshall, HC ; Solomayer, E ; Fehm, T ; Lester, J ; Winter, MC ; Horsman, JM ; Aft, R ; Brufsky, AM ; Llombart, HA

The Lancet (British edition), 2015-10, Vol.386 (10001), p.1353-1361 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Slamon, Dennis J ; Neven, Patrick ; Chia, Stephen ; Fasching, Peter A ; De Laurentiis, Michelino ; Im, Seock-Ah ; Petrakova, Katarina ; Bianchi, Giulia V ; Esteva, Francisco J ; Martín, Miguel ; Nusch, Arnd ; Sonke, Gabe S ; De la Cruz-Merino, Luis ; Beck, J. Thaddeus ; Pivot, Xavier ; Sondhi, Manu ; Wang, Yingbo ; Chakravartty, Arunava ; Rodriguez-Lorenc, Karen ; Taran, Tetiana ; Jerusalem, Guy

The New England journal of medicine, 2020-02, Vol.382 (6), p.514-524 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
10
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

GIANNI, Luca ; ROMIEU, Gilles H ; CHAN, Stephen ; WARDLEY, Andrew ; GREIL, Richard ; MOORE, Nicola ; PROT, Sylvie ; PALLAUD, Celine ; SEMIGLAZOV, Vladimir ; LICHINITSER, Michail ; SERRANO, Sergio V ; MANSUTTI, Mauro ; PIVOT, Xavier ; MARIANI, Paola ; ANDRE, Fabrice ; CHAN, Arlene ; LIPATOV, Oleg

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1719-1725 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (12.526)
  2. Revistas revisadas por pares (15.265)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (15.817)
  2. magazinearticle  (102)
  3. Anais de Congresso  (13)
  4. Web Resources  (1)
  5. Newsletter Articles  (1)
  6. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1973  (269)
  2. 1973Até1984  (1.152)
  3. 1985Até1996  (2.211)
  4. 1997Até2009  (6.143)
  5. Após 2009  (6.161)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (15.482)
  2. Japonês  (2.026)
  3. Francês  (390)
  4. Dinamarquês  (50)
  5. Russo  (35)
  6. Finlandês  (30)
  7. Norueguês  (19)
  8. Italiano  (5)
  9. Alemão  (2)
  10. Chinês  (1)
  11. Holandês  (1)
  12. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.